-+ 0.00%
-+ 0.00%
-+ 0.00%
Blackstone Life Sciences To Provide Johnson & Johnson With $750M In R&D Funding To Support Phase 3 Clinical Development Of OLN324, An Investigational Therapy For Serious Retinal Vascular Diseases
Share
Listen to the news

Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. ("Ollin").

The agreement is subject to the acquisition of Ollin by Johnson & Johnson, which is subject to customary closing conditions including receipt of regulatory approvals. As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending